| abstract |
The invention relates to a novel compound manufactured with the procedure of synthesis of bouncing Thymol and Carvacrol into one solid and stabile compound. Use of the compound as an active compound/potent entero-antiseptic for the treatment of infectious acute gastroenteritis in humans, caused by E. coli, Salmonella, Campylobacter, Shigella, Vibrio, Yersinia, Listeria, and other bacteria. Additionally, its second formulation, with the coated cellulose, is used as an active compound/potent entero-antiseptic for the treatment of chronic intestinal infections: Crohn's disease (inflammatory bowel disease - IBD). |